Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2026 | $20.00 | Equal Weight | Barclays |
| 12/9/2025 | $32.00 | Outperform | Wedbush |
| 11/5/2025 | $26.00 | Neutral → Outperform | Mizuho |
| 9/22/2025 | $50.00 | Market Perform → Outperform | BMO Capital Markets |
| 7/29/2025 | $22.00 | Underweight → Equal Weight | Barclays |
| 7/29/2025 | $13.00 | Mkt Perform | Bernstein |
| 7/29/2025 | $37.00 | Perform → Outperform | Oppenheimer |
| 7/29/2025 | $24.00 | Underweight → Neutral | Analyst |
Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling
For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene. Elevidys was previously approved under accelerated approval for amb
Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00
Wedbush initiated coverage of Sarepta Therapeutics with a rating of Outperform and set a new price target of $32.00
Mizuho upgraded Sarepta Therapeutics from Neutral to Outperform and set a new price target of $26.00
At a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative to the propensity-weighted external control group, as measured by Time to Rise (TTR) and 10-meter walk/run (10MWR). ELEVIDYS-treated patients showed an increasing treatment effect over time, with the functional gap versus the external control group significantly widening between Year 2 and Year 3 No new treatment-related safety signals were observed, consistent with the manageable safety profile observed with ELEVIDYS in ambulato
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 3-year topline functional results from patients treated in Part 1 of EMBARK (Study 9001-301), the global, randomized placebo-controlled Phase 3 study evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individuals with Duchenne muscular dystrophy who were aged four to seven at time of treatment. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presenta
Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025 Preliminary ELEVIDYS net product revenue totaled $110.4 million for the fourth quarter and $898.7 million for full-year 2025 Preliminary PMO net product revenues totaled $259.2 million for the fourth quarter and $965.6 million for full-year 2025 Preliminary year-end 2025 cash, cash equivalents, restricted cash and investments balance of approximately $953.8 million Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equ
8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)
8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)
8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
At a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative to the propensity-weighted external control group, as measured by Time to Rise (TTR) and 10-meter walk/run (10MWR). ELEVIDYS-treated patients showed an increasing treatment effect over time, with the functional gap versus the external control group significantly widening between Year 2 and Year 3 No new treatment-related safety signals were observed, consistent with the manageable safety profile observed with ELEVIDYS in ambulato
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 3-year topline functional results from patients treated in Part 1 of EMBARK (Study 9001-301), the global, randomized placebo-controlled Phase 3 study evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individuals with Duchenne muscular dystrophy who were aged four to seven at time of treatment. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presenta
Sarepta announces completion of the confirmatory trial commitment for its ultra-rare disease PMO therapies AMONDYS 45 and VYONDYS 53: While the ESSENCE study did not achieve statistical significance on its primary endpoint, results indicate positive and encouraging trends favoring therapy at 96 weeks Sarepta reports that the study was impacted by the COVID-19 pandemic and, when COVID-impacted data is excluded, meaningful treatment effect is seen on the primary endpoint ESSENCE supported favorable safety profile of AMONDYS 45 and VYONDYS 53 The Company intends to schedule a meeting with FDA to discuss path to a traditional approval based on the positive risk-benefits of the thera
NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior
- Veteran biopharmaceutical executive from GSK and Eli Lilly brings more than 30 years of experience to Sarepta's Board Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly's appointment, Sarepta's Board will comprise nine directors, eight of whom are independent. "Ms. Connelly is a seasoned board leader with extensive operating experience in biopharma and we're pleased to welcome her to the Sarepta Board of Directors as we work to
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)